O
PHAS

OrbiMed’s PhaseBio Pharmaceuticals, Inc. Common Stock PHAS Stock Holding History

OrbiMed’s Portfolio PHAS Stock Details PHAS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-177,113
Closed -$551K – 182
2021
Q3 		$551K Buy
+177,113
New +$591K 0.01% 169

Other funds holding PHAS

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ECM
ExodusPoint Capital Management New York $12.6B AUM 30.13% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

OrbiMed's PHAS Position: Q4 2021 in Review

OrbiMed sold out of PhaseBio Pharmaceuticals, Inc. Common Stock (PHAS) in Q4 2021, closing a stake of 177,113 shares — an estimated $551K sold.

OrbiMed first reported a position in PHAS in Q3 2021 and held it in 1 quarter. The position peaked at $551K in Q3 2021. 51 funds tracked by Wall St. Rank hold PHAS as of Q4 2021.

  • OrbiMed reported no remaining PhaseBio Pharmaceuticals, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • OrbiMed sold 177,113 PhaseBio Pharmaceuticals, Inc. Common Stock shares in Q4 2021, an estimated $551K.
  • OrbiMed first reported a position in PhaseBio Pharmaceuticals, Inc. Common Stock in Q3 2021 and held it in 1 quarter.
  • OrbiMed's PhaseBio Pharmaceuticals, Inc. Common Stock position peaked at $551K in Q3 2021.
  • 51 funds tracked by Wall St. Rank held PhaseBio Pharmaceuticals, Inc. Common Stock as of Q4 2021.

Based on OrbiMed's 13F filing for Q4 2021, filed 14 Feb 2022.